← ANALYST RATINGS · TIPRANKS
Monte Rosa Therapeutics (GLUE): analyst forecast and price target
Analyst consensus
Strong Buy8 Buy0 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $26.86, the highest $37.00, the lowest $19.00. The average is +175.7% from the last price of $9.74.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $10.00 → $10.50+5.0% | Hold | +7.8% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $10.00 → $10.50+5.0% | Hold | +7.8% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $9.50 → $10.00+5.3% | Hold | +2.7% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| Unknown Analyst | UBS | $17.00 → $19.00+11.8% | Buy | +95.1% | Assigned | 12.10.26on TipRanks Oct 14 10:05 | +2.2%next day −6.0% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 → $10.00−16.7% | Hold | +2.7% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.00 → $10.00−16.7% | Hold | +2.7% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.50 → $10.00−13.0% | Hold | +2.7% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $25.00 | Buy | +156.7% | Reiterated | 05.10.26on TipRanks 06:50 | −2.9%next day −4.4% · 5 days +2.0% | ↗ |
| Oliver McCammon★★★★★★★★★★#315 · hits 48% · avg +70.9% | LifeSci Capital | — | Buy | — | Reiterated | 02.10.26on TipRanks 09:45 | −7.5%next day −2.9% · 5 days −3.1% | ↗ |
| Unknown Analyst | Wedbush | $27.00 | Buy | +177.2% | Reiterated | 02.10.26on TipRanks 09:45 | −7.5%next day −2.9% · 5 days −3.1% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $37.00 | Buy | +279.9% | Reiterated | 02.10.26on TipRanks 07:15 | −7.5%next day −2.9% · 5 days −3.1% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $28.00 | Buy | +187.5% | Reiterated | 01.10.26on TipRanks Oct 2 07:10 | −5.8%next day −7.5% · 5 days −9.6% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $27.00 → $37.00+37.0% | Buy | +279.9% | Reiterated | 09.09.26on TipRanks Sep 16 21:02 | +0.4%next day +1.0% · 5 days −10.2% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $27.00 | Buy | +177.2% | Reiterated | 10.08.26on TipRanks Aug 11 08:07 | −0.3%next day −0.1% · 5 days −2.7% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $25.00 | Buy | +156.7% | Reiterated | 31.07.26on TipRanks 14:45 | −27.9%next day −8.3% · 5 days −7.4% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $29.00 | Buy | +197.7% | Assigned | 24.06.26on TipRanks 06:30 | +0.7%next day +3.7% · 5 days +13.5% | ↗ |
| Marc Frahm★★★★★★★★★★#223 · hits 56% · avg +25.8% | TD Cowen | — | Buy | — | Reiterated | 07.05.26on TipRanks 17:05 | −2.9%next day +4.3% · 5 days −6.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Monte Rosa Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $29.83 at a price of $11.93 (+150.1%); now: $26.86 at $9.74 (+175.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 3 | 5 | 8 | 10 | 14 |
| Buy | 5 | 4 | 6 | 5 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.21 (from $-0.56 to $0.10). Last quarter: $-0.43.
Sales
Next quarter’s sales estimate — $34M (from $0M to $67M). Last quarter: $9M.
Best top-analyst consensus in the sector · Healthcare
About Monte Rosa Therapeutics
- CEO: Markus Warmuth
- Employees: 173
- 321 Harrison Avenue, Boston, MA, 02118, US
- www.monterosatx.com
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Data from the stock’s TipRanks forecast page, read 54 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗